Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 19;11(4):563.
doi: 10.3390/cancers11040563.

Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy

Elisa Bergaggio  1 , Roberto Piva  2
Affiliations
Review

Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy

Elisa Bergaggio et al. Cancers (Basel). .

Abstract

Isocitrate dehydrogenases (IDHs) are enzymes that catalyze the oxidative decarboxylation of isocitrate, producing α-ketoglutarate (αKG) and CO2. The discovery of IDH1 and IDH2 mutations in several malignancies has brought to the approval of drugs targeting IDH1/2 mutants in cancers. Here, we summarized findings addressing the impact of IDH mutants in rare pathologies and focused on the relevance of non-mutated IDH enzymes in tumors. Several pieces of evidence suggest that the enzymatic inhibition of IDHs may have therapeutic potentials also in wild-type IDH cancers. Moreover, IDHs inhibition could enhance the efficacy of canonical cancer therapies, such as chemotherapy, target therapy, and radiotherapy. However, further studies are required to elucidate whether IDH proteins are diagnostic/prognostic markers, instrumental for tumor initiation and maintenance, and could be exploited as targets for anticancer therapy. The development of wild-type IDH inhibitors is expected to improve our understanding of a potential non-oncogenic addition to IDH1/2 activities and to fully address their applicability in combination with other therapies.

Keywords: DNA damage; combination therapy; isocitrate dehydrogenase (IDH); non-oncogenic addition; reactive oxygen species (ROS); wild-type IDH inhibitors; α-ketoglutarate (αKG).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
IDH inhibition enhances canonical cancer therapies efficacy. Schematic representation of the underlying mechanisms that increase the response to cancer therapies in presence of IDH1/2 inhibition.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition.
    Piva R, Gharari N, Labrador M, Mader S. Piva R, et al. Cancers (Basel). 2024 Sep 26;16(19):3280. doi: 10.3390/cancers16193280. Cancers (Basel). 2024. PMID: 39409901 Free PMC article.
  • Natural Metabolites as Modulators of Sensing and Signaling Mechanisms: Unlocking Anti-Ovarian Cancer Potential.
    Verma M, Mishra PS, Rahaman SKA, Gupta T, Sheikh AA, Sah AK, Sabrievna VA, Dzhuraevich KI, Abbas AM, Shalabi MG, Khamdamova M, Radjabovich BR, Karimova FR, Choudhary RK, Ghenaimi SA. Verma M, et al. Biomedicines. 2025 Jul 26;13(8):1830. doi: 10.3390/biomedicines13081830. Biomedicines. 2025. PMID: 40868085 Free PMC article. Review.
  • Comparative Analysis of Protein Folding Stability-Based Profiling Methods for Characterization of Biological Phenotypes.
    Bailey MA, Tang Y, Park HJ, Fitzgerald MC. Bailey MA, et al. J Am Soc Mass Spectrom. 2023 Mar 1;34(3):383-393. doi: 10.1021/jasms.2c00248. Epub 2023 Feb 20. J Am Soc Mass Spectrom. 2023. PMID: 36802530 Free PMC article.
  • Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer.
    Petralia F, Tignor N, Reva B, Koptyra M, Chowdhury S, Rykunov D, Krek A, Ma W, Zhu Y, Ji J, Calinawan A, Whiteaker JR, Colaprico A, Stathias V, Omelchenko T, Song X, Raman P, Guo Y, Brown MA, Ivey RG, Szpyt J, Guha Thakurta S, Gritsenko MA, Weitz KK, Lopez G, Kalayci S, Gümüş ZH, Yoo S, da Veiga Leprevost F, Chang HY, Krug K, Katsnelson L, Wang Y, Kennedy JJ, Voytovich UJ, Zhao L, Gaonkar KS, Ennis BM, Zhang B, Baubet V, Tauhid L, Lilly JV, Mason JL, Farrow B, Young N, Leary S, Moon J, Petyuk VA, Nazarian J, Adappa ND, Palmer JN, Lober RM, Rivero-Hinojosa S, Wang LB, Wang JM, Broberg M, Chu RK, Moore RJ, Monroe ME, Zhao R, Smith RD, Zhu J, Robles AI, Mesri M, Boja E, Hiltke T, Rodriguez H, Zhang B, Schadt EE, Mani DR, Ding L, Iavarone A, Wiznerowicz M, Schürer S, Chen XS, Heath AP, Rokita JL, Nesvizhskii AI, Fenyö D, Rodland KD, Liu T, Gygi SP, Paulovich AG, Resnick AC, Storm PB, Rood BR, Wang P; Children’s Brain Tumor Network; Clinical Proteomic Tumor Analysis Consortium. Petralia F, et al. Cell. 2020 Dec 23;183(7):1962-1985.e31. doi: 10.1016/j.cell.2020.10.044. Epub 2020 Nov 25. Cell. 2020. PMID: 33242424 Free PMC article.
  • Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics.
    Vagvala S, Guenette JP, Jaimes C, Huang RY. Vagvala S, et al. Cancer Imaging. 2022 Apr 18;22(1):19. doi: 10.1186/s40644-022-00455-5. Cancer Imaging. 2022. PMID: 35436952 Free PMC article. Review.
See all "Cited by" articles

References

    1. Geisbrecht B.V., Gould S.J. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J. Biol. Chem. 1999;274:30527–30533. doi: 10.1074/jbc.274.43.30527. - DOI - PubMed
    1. Ma T., Peng Y., Huang W., Liu Y., Ding J. The β and γ subunits play distinct functional roles in the α2βγ heterotetramer of human NAD-dependent isocitrate dehydrogenase. Sci. Rep. 2017;7:41882. doi: 10.1038/srep41882. - DOI - PMC - PubMed
    1. Wise D.R., Ward P.S., Shay J.E.S., Cross J.R., Gruber J.J., Sachdeva U.M., Platt J.M., DeMatteo R.G., Simon M.C., Thompson C.B. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. USA. 2011;108:19611–19616. doi: 10.1073/pnas.1117773108. - DOI - PMC - PubMed
    1. Metallo C.M., Gameiro P.A., Bell E.L., Mattaini K.R., Yang J., Hiller K., Jewell C.M., Johnson Z.R., Irvine D.J., Guarente L., et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012;481:380–384. doi: 10.1038/nature10602. - DOI - PMC - PubMed
    1. Mullen A.R., Wheaton W.W., Jin E.S., Chen P.-H., Sullivan L.B., Cheng T., Yang Y., Linehan W.M., Chandel N.S., DeBerardinis R.J. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2012;481:385–388. doi: 10.1038/nature10642. - DOI - PMC - PubMed